Biotech Values

[genisi]

pregnancy status is more relevant to the patient pool for MS...

That and Copaxone's much longer and better safety profile makes me think Gilenya will need to establish a long-term track record of safety before it becomes a standard first-line therapy, which it is shaping up to become. I expect that first users will be patients who have relapsed, have not respond or cannot tolerate current first line treatment. Then, I expect switchers to come from beta interferons since they have more side effects and lower efficacy.